NOT FOR DISTRIBUTION
Header cover image

Market Cap

UK£17.0m

Last Updated

2021/09/19 17:43 UTC

Data Sources

Company Financials +

Executive Summary

Evgen Pharma plc, a clinical stage drug development company, focuses in the development of sulforaphane-based compunds for the treatment of multiple diseases. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Evgen Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EVG is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: EVG's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.


Market Performance


7 Day Return

1.6%

EVG

-1.5%

GB Biotechs

-1.0%

GB Market


1 Year Return

-47.8%

EVG

30.4%

GB Biotechs

19.2%

GB Market

Return vs Industry: EVG underperformed the UK Biotechs industry which returned 30.4% over the past year.

Return vs Market: EVG underperformed the UK Market which returned 19.2% over the past year.


Shareholder returns

EVGIndustryMarket
7 Day1.6%-1.5%-1.0%
30 Day21.6%-0.6%-0.7%
90 Day-21.5%5.5%0.5%
1 Year-47.8%-47.8%30.8%30.4%24.1%19.2%
3 Year-68.2%-68.2%38.4%36.5%15.4%2.5%
5 Year-79.0%-79.0%63.4%60.1%35.4%10.7%

Long-Term Price Volatility Vs. Market

How volatile is Evgen Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Evgen Pharma undervalued compared to its fair value and its price relative to the market?

1.44x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EVG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EVG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EVG is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: EVG is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EVG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EVG is good value based on its PB Ratio (1.4x) compared to the GB Biotechs industry average (6.5x).


Future Growth

How is Evgen Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-33.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EVG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EVG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EVG is forecast to have no revenue next year.

High Growth Revenue: EVG is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EVG is forecast to be unprofitable in 3 years.


Past Performance

How has Evgen Pharma performed over the past 5 years?

4.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EVG is currently unprofitable.

Growing Profit Margin: EVG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EVG is unprofitable, but has reduced losses over the past 5 years at a rate of 4.8% per year.

Accelerating Growth: Unable to compare EVG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EVG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (19.9%).


Return on Equity

High ROE: EVG has a negative Return on Equity (-22.64%), as it is currently unprofitable.


Financial Health

How is Evgen Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: EVG's short term assets (£12.3M) exceed its short term liabilities (£607.0K).

Long Term Liabilities: EVG has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: EVG is debt free.

Reducing Debt: EVG had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EVG has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: EVG has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 9% each year.


Dividend

What is Evgen Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EVG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EVG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EVG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EVG's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Huw Jones (61 yo)

0.92

Tenure

UK£224,403

Compensation

Dr. Huw Jones, BSc, Ph.D. serves as Chief Executive Officer at Evgen Pharma plc since October 1, 2020. He has been Chief Executive Officer at Chronos Therapeutics Ltd. since December 2012 and serves as its...


CEO Compensation Analysis

Compensation vs Market: Huw's total compensation ($USD308.64K) is about average for companies of similar size in the UK market ($USD327.28K).

Compensation vs Earnings: Insufficient data to compare Huw's compensation with company performance.


Leadership Team

Experienced Management: EVG's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: EVG's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 100.2%.


Top Shareholders

Company Information

Evgen Pharma plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Evgen Pharma plc
  • Ticker: EVG
  • Exchange: AIM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£17.043m
  • Shares outstanding: 274.89m
  • Website: https://evgen.com

Number of Employees


Location

  • Evgen Pharma plc
  • Alderley Park, Block 24
  • Suite 24G13
  • Nether Alderley
  • Cheshire
  • SK10 4TG
  • United Kingdom

Listings


Biography

Evgen Pharma plc, a clinical stage drug development company, focuses in the development of sulforaphane-based compunds for the treatment of multiple diseases. Its core technology is Sulforadex, a means of...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/19 17:43
End of Day Share Price2021/09/17 00:00
Earnings2021/03/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.